News

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

EssilorLuxottica and MidEuropa recently entered into an agreement that will allow EssilorLuxottica to acquire Optegra, building upon its med-tech strategy.

Prof Malik shared his presentation, titled "An eye on neurodegenerative diseases: Challenging the dogma," at this year's International SPECTRALIS Symposium

Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium

Amneal Pharmaceuticals received FDA approval for its prednisolone acetate ophthalmic suspension, a steroid eye inflammation treatment referencing Allergan’s Pred Forte, with a US launch planned for Q3 2025.

Lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients

Harrow expects BYQLOVI to be commercially available in the fourth quarter of 2025.

The novel preservative-free eye drop therapy for glaucoma aims to improve IOP control and patient adherence with a fixed-dose combination.

Researchers hypothesize that lamivudine was effective in the clinical trial against DME because the drug blocks the activity of inflammasomes.

A new study compared results to determine a more comprehensive understanding of the relationship between the grade of surgeon and ISBCS outcomes

ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

Compared with penicillin, investigators reported no significant differences in the incidence of ophthalmologic manifestations among patients treated with ceftriaxone.

Cabozantinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor, a drug used as a therapy for several malignancies.

CLARUS 700, the advanced retinal imaging system, captures 133 degrees in a single image and up to 267 degrees with multiple images.

FDA noted that the US phase 2 trial may serve as 1 of the 2 pivotal trials required for NDA filing.

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery

More than 35 lectures across seven topics, plus a keynote address, will be featured during the meeting

In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the development of vision restoration therapies.

Siegfried Priglinger, MD discussed research he presented focused on pediatric patients with inherited retinal diseases with an emphasis on studies into the RPE65 gene.

The gift will be used to treat and potentially cure eye diseases such as macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal protein buildup in the stromal layer of the cornea.

Mark Daly discusses the transformative role of AI in ophthalmology, highlighting its potential to enhance patient care and streamline physician workflows.

Brazilian regulatory authority ANVISA grants marketing authorization for Ranivisio.